Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Monophosphothiamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | TKT | P29401 | 9/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monophosphothiamine SCHEMBL29733068 | 0.99 | TDP1 (0.98) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL94443 | 0.99 | TDP1 (0.98) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL3681710 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL642271 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL9159014 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL23151818 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL17768676 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL29373566 | 0.98 | TDP1 (1.00) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL94444 | 0.98 | TDP1 (1.00) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL4302184 | 0.97 | TDP1 (0.94) | TDP1TKTLMNAHSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | claimed |
| EP-0558960-A1 | Medicament for the prophylaxis and treatment of the neurologic and psychiatric disorders caused by alcohol abuse, which contains thiamine, folic acid and cobalamine | WÖRWAG PHARMA GmbH (DE) | 1993-09-08 | — | — | EP | claimed |
| US-12263198-B1 | Compositions and methods of improving ruminant performance | RALCO NUTRITION, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-117545459-A | Cleaning composition and method for producing same | 日本乐敦制药株式会社 | 2024-02-09 | — | — | CN | disclosed |
| CN-116870157-A | Composition for improving skin disorders | 日本乐敦制药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| CN-116685305-A | Cleaning composition | 日本乐敦制药株式会社 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023017790-A1 | CLEANING COMPOSITION AND PRODUCTION METHOD FOR SAME | ロート製薬株式会社 | 2023-02-16 | — | — | WO | disclosed |
| CN-111107831-B | Composition for supplementing the taste of young women | 日本乐敦制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-11286212-B2 | Foliar fertilizer compositions and methods for using same | YAMASHITA THOMAS T (US) | 2022-03-29 | — | — | US | disclosed |
| CN-113164799-A | Composition comprising ethers synthesized from fatty alcohols and glycerol | 日本乐敦制药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| EP-0544759-A1 | DETOXIFICATION OF SOIL. | YAMASHITA THOMAS T (US) | 1993-06-09 | — | — | EP | disclosed |
| EP-0514451-A1 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. | UNIV TEXAS (US) | 1992-11-25 | — | — | EP | disclosed |
| WO-1992003393-A1 | DETOXIFICATION OF SOIL | YAMASHITA THOMAS T (US) | 1992-03-05 | — | — | WO | disclosed |
| EP-0433394-A4 | METHOD OF APPLYING ENERGY, CARBON SKELETON AND NUTRIENT MATERIALSTO VEGETATION | — | 1991-09-25 | — | — | EP | disclosed |
| WO-1991013844-A1 | METHOD AND COMPOSITION FOR PROMOTING AND CONTROLLING GROWTH OF PLANTS | YAMASHITA THOMAS T (US) | 1991-09-19 | — | — | WO | disclosed |
| WO-1991011117-A2 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-08-08 | — | — | WO | disclosed |
| EP-0433394-A1 | METHOD OF APPLYING ENERGY, CARBON SKELETON AND NUTRIENT MATERIALSTO VEGETATION. | YAMASHITA THOMAS T (US) | 1991-06-26 | — | — | EP | disclosed |
| WO-1990002719-A1 | METHOD OF APPLYING ENERGY, CARBON SKELETON AND NUTRIENT MATERIALSTO VEGETATION | YAMASHITA THOMAS T (US) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | TDP1 3154/4885TKT 501/4885LMNA 1677/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | TDP1 3346/4885TKT 531/4885LMNA 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.